Key Highlights

  • Humana (NYSE:HUM) rose 14.64% to USD 443.78 in the October 9, 2026 session, per published market data, after federal regulators released 2027 Medicare Advantage Star Ratings on the evening of October 8.
  • The main catalyst is that its largest Medicare Advantage contract rose to 4 stars from 3.5 stars, which restores eligibility for federal quality Bonus payments tied to higher ratings.
  • Reportedly, the financial benefit arrives mainly in 2028 payments, and one analyst estimate cited by those reports put the gain at USD 3 billion or more in revenue.
  • Humana (NYSE:HUM) had already traded sharply higher after hours on October 8, so the earlier jump and the October 9 session move overlap and should not be added together.

The Ratings Release Behind the Jump

Humana (NYSE:HUM) gained 14.64% to USD 443.78 in the October 9, 2026 session, giving it a Market Value near USD 53.29 billion, according to published market data. Published reports tie the move to the Medicare Advantage Star Ratings for 2027, which the Centers for Medicare and Medicaid Services released on Thursday, October 8. Humana's largest contract moved up to 4 stars from 3.5 stars. Reports described a rise of about 13% in after-hours trading that evening and another account of 16.5%, so those figures overlap with the October 9 session and are not additive. The company has not been quoted here beyond what the published ratings show, and no separate Humana release explaining the move was found.

Why Half a Star Is Worth So Much

Medicare Advantage contracts rated 4 stars or higher qualify for quality bonus payments and larger rebates, which raise the funding an insurer receives per member. Humana's history shows the stakes: after its 2024 ratings, the share of its members in 4 star plans reportedly fell from 94% to 25% for the following year. Because ratings published now set payments for a later plan year, the 2027 ratings feed mostly into 2028 revenue, as reported. TD Cowen analyst Ryan Langston estimated a gain of USD 3 billion or more in 2028 revenue, a unconfirmed estimate that is an opinion, not a company figure. Rival Alignment Healthcare moved the other way as its largest contract slipped below 4 stars.

Recent Results and What Could Go Wrong

In its July 29, 2026 results, Humana reported second-quarter Revenue of USD 40.87 billion, adjusted Earnings of USD 7.61 per share and GAAP earnings of USD 5.73 per share. It affirmed full-year adjusted earnings of at least USD 9.00 per share while lowering GAAP guidance to at least USD 6.52 from USD 8.36. The second-quarter insurance benefit ratio was 91.2%, and full-year guidance is 92.75%, plus or minus 25 basis points. Risks include medical cost trends, the long wait until 2028 for bonus dollars, ratings methodology changes and the chance that a 14.64% rise already prices in much of the benefit. Humana (NYSE:HUM) will also face open enrollment, which begins October 15.

Where Things Stand

Humana (NYSE:HUM) rose in the October 9, 2026 session because of a verified catalyst: its largest Medicare Advantage contract earned 4 stars in the 2027 ratings released October 8. The benefit is mostly a 2028 payment story, and the shares already moved sharply after hours. The balance of evidence points to better long-run earnings power, tempered by cost trends and valuation. Watch open enrollment, contract-level ratings detail and the next quarterly report.